Aida Pharmaceuticals announced that its anti-cancer agent, a gene therapy called Rh-Apo2L, is in the middle of its Phase II trials. Rh-Apo2L is a broad spectrum genetic agent that induces apoptosis (cell death). The goal of the Phase IIa trial is to determine three tumor types against which the drug has the most efficacy and also provide the largest markets. More details...

Stock Symbol: (OTCBB: AIDA)